FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896535802> ?p ?o ?g. }

• W2896535802 endingPage "110" @default.
• W2896535802 startingPage "103" @default.
• W2896535802 abstract "Metastatic renal cell carcinoma (mRCC) is a tumor entity with poor prognosis due to limited therapy options. Tyrosine kinase inhibitors (TKIs), the novel targeted agents have been used for the treatment of mRCC and have shown efficacy. Interferon (IFN)-α is also one of the most frequently used agents in immunotherapy. However, drug resistance needs to be overcome to achieve a sufficiently positive effect. Interleukin-6 (IL-6), which induce suppressor of cytokine signaling-3 (SOCS3) expression, is one of the factors associated with poor prognosis of patients with renal cell carcinoma (RCC). To analyze the influence of IL-6 in drug resistance of RCC, anti-IL-6 receptor antibody was used in combination with IFN or TKIs. The SOCS3 mRNA expression level was significantly increased by IFN-α stimulation in 786-O RCC cells which were resistant to IFN, but not in ACHN cells that were sensitive to IFN. The overexpression of SOCS3 by gene transfection in ACHN significantly inhibited the growth-inhibitory effect of IFN-α. An in vivo study demonstrated that co-administration of SOCS3-targeted siRNA promoted INF-α-induced cell death and growth suppression in 786-O cell xenograft. SOCS3 could be a key component in the resistance to interferon treatment of renal cell carcinoma. Because SOCS3 is rapidly up-regulated by IL-6 and a negative regulator of cytokine signaling, IL-6 expression on RCC cells was also analyzed and the 786-O cells showed the high level of IL-6 mRNA expression under the condition of interferon stimulation. IL-6R antibody, tocilizumab, significantly suppressed cell proliferation in 786-O cells by interferon stimulation accompanied with phosphorylation of STAT1 and inhibited SOCS3 expression. The in vivo effects of combination therapy with tocilizumab and interferon showed significant suppression of 786-O tumor growth in a xenograft model. We also hypothesized that TKI resistance and IL-6 secretion are causally connected. And we found that 786-O RCC cells secrete high IL-6 levels after low dose stimulation with the TKIs sorafenib, sunitinib and pazopanib, inducing activation of AKT-mTOR pathway, NFκB, HIF-2α and VEGF expression. Tocilizumab neutralizes the AKT-mTOR pathway activation and results in reduced proliferation. A combination therapy with tocilizumab and TKI suppresses 786-O tumor growth and inhibits angiogenesis in vivo more efficient than TKI alone. Our findings suggest that IL-6 could induce drug resistance on RCC, and combination therapy of IL-6R inhibitors and IFN/TKIs may represent a novel therapeutic approach for RCC treatment." @default.
• W2896535802 created "2018-10-26" @default.
• W2896535802 creator A5008746241 @default.
• W2896535802 creator A5040311432 @default.
• W2896535802 creator A5042828451 @default.
• W2896535802 creator A5046004476 @default.
• W2896535802 creator A5066138488 @default.
• W2896535802 creator A5068096040 @default.
• W2896535802 creator A5073702475 @default.
• W2896535802 creator A5075866903 @default.
• W2896535802 creator A5076149190 @default.
• W2896535802 creator A5077496785 @default.
• W2896535802 creator A5077880103 @default.
• W2896535802 creator A5080573589 @default.
• W2896535802 creator A5084707639 @default.
• W2896535802 creator A5085526247 @default.
• W2896535802 creator A5091032115 @default.
• W2896535802 date "2018-01-01" @default.
• W2896535802 modified "2023-10-01" @default.
• W2896535802 title "Interleukin-6 induces drug resistance in renal cell carcinoma" @default.
• W2896535802 cites W1491779959 @default.
• W2896535802 cites W1548640328 @default.
• W2896535802 cites W1668039320 @default.
• W2896535802 cites W1852876364 @default.
• W2896535802 cites W1928193662 @default.
• W2896535802 cites W1931245889 @default.
• W2896535802 cites W1969674061 @default.
• W2896535802 cites W1976210019 @default.
• W2896535802 cites W1979328748 @default.
• W2896535802 cites W1986609132 @default.
• W2896535802 cites W1994001783 @default.
• W2896535802 cites W1999966467 @default.
• W2896535802 cites W2000110198 @default.
• W2896535802 cites W2001775267 @default.
• W2896535802 cites W2004349741 @default.
• W2896535802 cites W2007998678 @default.
• W2896535802 cites W2011803760 @default.
• W2896535802 cites W2016757878 @default.
• W2896535802 cites W2017018900 @default.
• W2896535802 cites W2023952988 @default.
• W2896535802 cites W2032993790 @default.
• W2896535802 cites W2041881143 @default.
• W2896535802 cites W2044227662 @default.
• W2896535802 cites W2053426387 @default.
• W2896535802 cites W2059080581 @default.
• W2896535802 cites W2064041774 @default.
• W2896535802 cites W2067363890 @default.
• W2896535802 cites W2082331198 @default.
• W2896535802 cites W2086840459 @default.
• W2896535802 cites W2091546244 @default.
• W2896535802 cites W2093442991 @default.
• W2896535802 cites W2094232612 @default.
• W2896535802 cites W2099088585 @default.
• W2896535802 cites W2101899879 @default.
• W2896535802 cites W2105589914 @default.
• W2896535802 cites W2105677187 @default.
• W2896535802 cites W2107567753 @default.
• W2896535802 cites W2112009920 @default.
• W2896535802 cites W2115201803 @default.
• W2896535802 cites W2116949558 @default.
• W2896535802 cites W2123769946 @default.
• W2896535802 cites W2129385913 @default.
• W2896535802 cites W2137870051 @default.
• W2896535802 cites W2143782771 @default.
• W2896535802 cites W2146295064 @default.
• W2896535802 cites W2146853858 @default.
• W2896535802 cites W2148706732 @default.
• W2896535802 cites W2149456801 @default.
• W2896535802 cites W2152152351 @default.
• W2896535802 cites W2164638888 @default.
• W2896535802 cites W2166010840 @default.
• W2896535802 cites W2222086386 @default.
• W2896535802 cites W2409057459 @default.
• W2896535802 cites W2463972652 @default.
• W2896535802 cites W2507992840 @default.
• W2896535802 cites W2514362149 @default.
• W2896535802 cites W2552236699 @default.
• W2896535802 cites W2569614793 @default.
• W2896535802 cites W2610313261 @default.
• W2896535802 cites W2736535396 @default.
• W2896535802 cites W2786987313 @default.
• W2896535802 cites W4298379398 @default.
• W2896535802 doi "https://doi.org/10.5387/fms.2018-15" @default.
• W2896535802 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6305783" @default.
• W2896535802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30369518" @default.
• W2896535802 hasPublicationYear "2018" @default.
• W2896535802 type Work @default.
• W2896535802 sameAs 2896535802 @default.
• W2896535802 citedByCount "36" @default.
• W2896535802 countsByYear W28965358022019 @default.
• W2896535802 countsByYear W28965358022020 @default.
• W2896535802 countsByYear W28965358022021 @default.
• W2896535802 countsByYear W28965358022022 @default.
• W2896535802 countsByYear W28965358022023 @default.
• W2896535802 crossrefType "journal-article" @default.
• W2896535802 hasAuthorship W2896535802A5008746241 @default.
• W2896535802 hasAuthorship W2896535802A5040311432 @default.
• W2896535802 hasAuthorship W2896535802A5042828451 @default.

• next